Dergiler / Journal of Experimental and Clinical Medicine / 2022 / Cilt: 39 - Sayı: 3

Effects of beta-1,3-D glucan on systemic bortezomib treated rat pancreas

Sayfa
743–748
DOI
—

Abstract

Bortezomib, selective inhibitor of the 26S proteasome, is used for treatment of some types of cancer and immunosuppressive therapies. B-1,3-(D)-glucan, a synthetic antioxidant is used complementary medical treatment for human. This study was conducted to investigate the effects of the antioxidant Beta-1,3-D glucan on rat pancreas treated with systemic bortezomib. In the study, 36 Sprague-Dawley adult male rats were divided into four groups: control (C), bortezomib (BZ), β-1, 3-D-glucan (BD) and bortezomib + β-1,3- (D) –glukan (BZ+BD). Each group was divided into two subgroups (48 or 72 hours), depending on the time of sacrification. After experiments, immunohistochemical, stereological and histopathological changes in all rat pancreatic tissues were examined. It was determined increased degenerative, vacuolated serous acini cells and inflammatory cell infiltrations in the groups of BZ and BZ+BG. In immunohistochemical analysis, densities of insulin positive cells were decreased in the groups of BZ and BZ+BG. Furthermore, in stereological mean volume of serous acinus analysis, significantly increases were detected in the groups of BZ and BZ+BG (p